Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review

被引：0
作者：
Borella, Fulvio [1 ]
Carosso, Marco [1 ]
Chiparo, Maria Pia [1 ]
Ferraioli, Domenico [2 ]
Bertero, Luca [3 ]
Gallio, Niccolo [4 ]
Preti, Mario [1 ]
Cusato, Jessica [5 ]
Valabrega, Giorgio [6 ]
Revelli, Alberto [4 ]
Marozio, Luca [1 ]
Cosma, Stefano [1 ]
机构：
[1] Univ Turin, Dept Surg Sci, Gynecol & Obstet 1U, I-10126 Turin, Italy
[2] Comprehens Canc Ctr, Dept Gynecol, Leon Berard, F-69008 Lyon, France
[3] Univ Turin, Dept Med Sci, Pathol Unit, I-10126 Turin, Italy
[4] Univ Turin, Dept Surg Sci, Gynecol & Obstet 2U, I-10126 Turin, Italy
[5] Univ Turin, Dept Med Sci, Lab Clin Pharmacol & Pharmacogenet, I-10149 Turin, Italy
[6] Univ Turin, Ordine Mauriziano Hosp, Dept Oncol, Med Oncol, I-10128 Turin, Italy
来源：
PATHOGENS | 2025年 / 14卷 / 02期
关键词：
ovarian cancer; oncolytic virus; virus; adenovirus; herpes simplex virus; vaccinia virus; myxoma virus; vesicular stomatitis virus; HERPES-SIMPLEX-VIRUS; VESICULAR STOMATITIS-VIRUS; CONDITIONALLY-REPLICATIVE ADENOVIRUS; COLONY-STIMULATING FACTOR; YEAST CYTOSINE DEAMINASE; SODIUM-IODIDE SYMPORTER; PHASE-I TRIAL; VACCINIA VIRUS; MEASLES-VIRUS; GENE-TRANSFER;
D O I：
10.3390/pathogens14020140
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Ovarian cancer (OC) remains the most lethal gynecologic malignancy with limited effective treatment options. Oncolytic viruses (OVs) have emerged as a promising therapeutic approach for cancer treatment, capable of selectively infecting and lysing cancer cells while stimulating anti-tumor immune responses. Preclinical studies have demonstrated significant tumor regression and prolonged survival in OC models using various OVs, such as herpes simplex. Early-phase clinical trials have shown a favorable safety profile, though the impact on patient survival has been modest. Current research focuses on combining OVs with other treatments like immune checkpoint inhibitors to enhance their efficacy. We provide a comprehensive overview of the current understanding and future directions for utilizing OVs in the management of OC.
引用
收藏
页数：27
相关论文
共 192 条
  • [1] Recognition of Reovirus RNAs by the Innate Immune System
    Abad, Andrew T.
    Danthi, Pranav
    [J]. VIRUSES-BASEL, 2020, 12 (06):
  • [2] Vesicular Stomatitis Virus: Insights into Pathogenesis, Immune Evasion, and Technological Innovations in Oncolytic and Vaccine Development
    Ahmed, Mohamed Mustaf
    Okesanya, Olalekan John
    Ukoaka, Bonaventure Michael
    Ibrahim, Adamu Muhammad
    Lucero-Prisno III, Don Eliseo
    [J]. VIRUSES-BASEL, 2024, 16 (12):
  • [3] The advent of oncolytic virotherapy in oncology: The Rigvir® story
    Alberts, Peteris
    Tilgase, Andra
    Rasa, Agnija
    Bandere, Katrina
    Venskus, Dite
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 837 : 117 - 126
  • [4] Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
    Aldrak, Norah
    Alsaab, Sarah
    Algethami, Aliyah
    Bhere, Deepak
    Wakimoto, Hiroaki
    Shah, Khalid
    Alomary, Mohammad N.
    Zaidan, Nada
    [J]. CELLS, 2021, 10 (06)
  • [5] Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity
    Allen, Cory
    Paraskevakou, Georgia
    Iankov, Ianko
    Giannini, Caterina
    Schroeder, Mark
    Sarkaria, Jann
    Schroeder, Mark
    Puri, Raj K.
    Russell, Stephen J.
    Galanis, Evanthia
    [J]. MOLECULAR THERAPY, 2008, 16 (09) : 1556 - 1564
  • [6] Oncolytic reovirus induces ovarian cancer cell apoptosis in a TLR3-dependent manner
    An, Yuanyuan
    Wang, Xianyao
    Wu, Xuxian
    Chen, Liang
    Yang, Yichen
    Lin, Xiaojin
    Wang, Nianxue
    Duan, Jiangyao
    Long, Shiqi
    Zhao, Xing
    [J]. VIRUS RESEARCH, 2021, 301
  • [7] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
    Andtbacka, Robert H. I.
    Kaufman, Howard L.
    Collichio, Frances
    Amatruda, Thomas
    Senzer, Neil
    Chesney, Jason
    Delman, Keith A.
    Spitler, Lynn E.
    Puzanov, Igor
    Agarwala, Sanjiv S.
    Milhem, Mohammed
    Cranmer, Lee
    Curti, Brendan
    Lewis, Karl
    Ross, Merrick
    Guthrie, Troy
    Linette, Gerald P.
    Daniels, Gregory A.
    Harrington, Kevin
    Middleton, Mark R.
    Miller, Wilson H., Jr.
    Zager, Jonathan S.
    Ye, Yining
    Yao, Bin
    Li, Ai
    Doleman, Susan
    VanderWalde, Ari
    Gansert, Jennifer
    Coffin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2780 - U98
  • [8] Measles to the Rescue: A Review of Oncolytic Measles Virus
    Aref, Sarah
    Bailey, Katharine
    Fielding, Adele
    [J]. VIRUSES-BASEL, 2016, 8 (10):
  • [9] Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer
    Baird, S. K.
    Aerts, J. L.
    Eddaoudi, A.
    Lockley, M.
    Lemoine, N. R.
    McNeish, I. A.
    [J]. ONCOGENE, 2008, 27 (22) : 3081 - 3090
  • [10] Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
    Basnet, Saru
    Van der Heijden, Mirte
    Quixabeira, Dafne C. A.
    Jirovec, Elise
    Gronberg-Vaha-Koskela, Susanna A. M.
    Clubb, James H. A.
    Kanerva, Anna
    Pakola, Santeri
    Haybout, Lyna
    Arias, Victor
    Hemminki, Otto
    Kudling, Tatiana
    Zafar, Sadia
    Cervera-Carrascon, Victor
    Santos, Joao M.
    Hemminki, Akseli
    [J]. MOLECULAR THERAPY, 2024, 32 (09) : 3114 - 3127
12345678910